Logo image of INKT

MINK THERAPEUTICS INC (INKT) Stock Fundamental Analysis

NASDAQ:INKT - Nasdaq - US6036931029 - Common Stock - Currency: USD

6.89  +0.29 (+4.39%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to INKT. INKT was compared to 572 industry peers in the Biotechnology industry. INKT has a bad profitability rating. Also its financial health evaluation is rather negative. INKT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INKT has reported negative net income.
In the past year INKT has reported a negative cash flow from operations.
INKT had negative earnings in each of the past 5 years.
In the past 5 years INKT always reported negative operating cash flow.
INKT Yearly Net Income VS EBIT VS OCF VS FCFINKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of INKT (-186.86%) is worse than 89.73% of its industry peers.
Industry RankSector Rank
ROA -186.86%
ROE N/A
ROIC N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INKT Yearly ROA, ROE, ROICINKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 2K 4K 6K

1.3 Margins

INKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INKT Yearly Profit, Operating, Gross MarginsINKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, INKT has more shares outstanding
INKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INKT Yearly Shares OutstandingINKT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
INKT Yearly Total Debt VS Total AssetsINKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

INKT has an Altman-Z score of -27.13. This is a bad value and indicates that INKT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -27.13, INKT is not doing good in the industry: 90.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.13
ROIC/WACCN/A
WACCN/A
INKT Yearly LT Debt VS Equity VS FCFINKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.89 indicates that INKT may have some problems paying its short term obligations.
The Current ratio of INKT (0.89) is worse than 89.56% of its industry peers.
A Quick Ratio of 0.89 indicates that INKT may have some problems paying its short term obligations.
With a Quick ratio value of 0.89, INKT is not doing good in the industry: 88.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.89
INKT Yearly Current Assets VS Current LiabilitesINKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

INKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.58%, which is quite impressive.
EPS 1Y (TTM)46.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

INKT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.85% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.79%
EPS Next 2Y25.81%
EPS Next 3Y15.97%
EPS Next 5Y18.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INKT Yearly Revenue VS EstimatesINKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
INKT Yearly EPS VS EstimatesINKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INKT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INKT Price Earnings VS Forward Price EarningsINKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INKT Per share dataINKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as INKT's earnings are expected to grow with 15.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.81%
EPS Next 3Y15.97%

More info and screens

0

5. Dividend

5.1 Amount

INKT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINK THERAPEUTICS INC

NASDAQ:INKT (1/30/2025, 5:20:01 PM)

6.89

+0.29 (+4.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners2.39%
Inst Owner Change0%
Ins Owners7.81%
Ins Owner Change0.32%
Market Cap273.05M
Analysts86
Price Target6.8 (-1.31%)
Short Float %1.22%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.05%
Min EPS beat(2)31.37%
Max EPS beat(2)38.73%
EPS beat(4)3
Avg EPS beat(4)24.37%
Min EPS beat(4)-2.3%
Max EPS beat(4)38.73%
EPS beat(8)6
Avg EPS beat(8)18.75%
EPS beat(12)9
Avg EPS beat(12)20.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)64.29%
EPS NY rev (1m)0%
EPS NY rev (3m)21.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-232.92%
ROA(5y)-574.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.89
Altman-Z -27.13
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)185.59%
Cap/Depr(5y)359.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y58.79%
EPS Next 2Y25.81%
EPS Next 3Y15.97%
EPS Next 5Y18.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.75%
OCF growth 3YN/A
OCF growth 5YN/A